CADASIL management or what to do when there is little one can do

References

• Kalimo H, Ruchoux MM, Viitanen M, Kalaria RN. CADASIL: a common form of hereditary arteriopathy causing brain infarcts and dementia. Brain Pathol.12(3), 371–384 (2002).
   PubMed Web of Science ®Google Scholar
• Dotti MT, Federico A, Mazzei R et al. The spectrum of Notch3 mutations in 28 Italian CADASIL families. J. Neurol. Neurosurg. Psychiatry76(5), 736–738 (2005).
   PubMedGoogle Scholar
• Razvi SS, Davidson R, Bone I, Muir KW. The prevalence of cerebral autosomal dominant arteriopathy with subcortical infarcts and leucoencephalopathy (CADASIL) in the west of Scotland. J. Neurol. Neurosurg. Psychiatry76(5), 739–741 (2005).
   PubMed Web of Science ®Google Scholar
• Opherk C, Peters N, Herzog J, Luedtke R, Dichgans M. Long-term prognosis and causes of death in CADASIL: a retrospective study in 411 patients. Brain127(Pt 11), 2533–2539 (2004).
   PubMed Web of Science ®Google Scholar
• Davous P. The natural history of CADASIL. Stroke30(10), 2247 (1999).
   PubMedGoogle Scholar
• Desmond DW, Moroney JT, Lynch T, Chan S, Chin SS, Mohr JP. The natural history of CADASIL: a pooled analysis of previously published cases. Stroke30(6), 1230–1233 (1999).
   PubMed Web of Science ®Google Scholar
• Joutel A, Corpechot C, Ducros A et al.Notch3 mutations in CADASIL, a hereditary adult-onset condition causing stroke and dementia. Nature383(6602), 707–710 (1996).
   PubMed Web of Science ®Google Scholar
• Artavanis-Tsakonas S, Matsuno K, Fortini ME. Notch signaling. Science268(5208), 225–232 (1995).
   PubMed Web of Science ®Google Scholar
• Lindsell CE, Boulter J, DiSibio G, Gossler A, Weinmaster G. Expression patterns of Jagged, Delta1, Notch1, Notch2, and Notch3 genes identify ligand-receptor pairs that may function in neural development. Mol. Cell. Neurosci.8(1), 14–27 (1996).
   PubMed Web of Science ®Google Scholar
• Villa N, Walker L, Lindsell CE, Gasson J, Iruela-Arispe ML, Weinmaster G. Vascular expression of Notch pathway receptors and ligands is restricted to arterial vessels. Mech. Dev.108(1–2), 161–164 (2001).
   PubMed Web of Science ®Google Scholar
• Domenga V, Fardoux P, Lacombe P et al. Notch3 is required for arterial identity and maturation of vascular smooth muscle cells. Genes Dev.18(22), 2730–2735 (2004).
   PubMed Web of Science ®Google Scholar
• Lesnik Oberstein SA, van Duinen SG, van den Boom R et al. Evaluation of diagnostic NOTCH3 immunostaining in CADASIL. Acta Neuropathol.106(2), 107–111 (2003).
   PubMed Web of Science ®Google Scholar
• Ihalainen S, Soliymani R, Iivanainen E et al. Proteome analysis of cultivated vascular smooth muscle cells from a CADASIL patient. Mol. Med.13(5–6), 305–314 (2007).
   PubMed Web of Science ®Google Scholar
• Spinner NB. CADASIL: Notch signaling defect or protein accumulation problem? J. Clin. Invest.105(5), 561–562 (2000).
   PubMed Web of Science ®Google Scholar
• Vikelis M, Xifaras M, Mitsikostas DD. CADASIL: a short review of the literature and a description of the first family from Greece. Funct. Neurol.21(2), 77–82 (2006).
   PubMedGoogle Scholar
• Joutel A, Vahedi K, Corpechot C et al. Strong clustering and stereotyped nature of NOTCH3 mutations in CADASIL patients. Lancet350(9090), 1511–1515 (1997).
   PubMed Web of Science ®Google Scholar
• Joutel A, Andreux F, Gaulis S et al. The ectodomain of the Notch3 receptor accumulates within the cerebrovasculature of CADASIL patients. J. Clin. Invest.105(5), 597–605 (2000).
   PubMed Web of Science ®Google Scholar
• Ishiko A, Shimizu A, Nagata E, Takahashi K, Tabira T, Suzuki N. Notch3 ectodomain is a major component of granular osmiophilic material (GOM) in CADASIL. Acta Neuropathol.112(3), 333–339 (2006).
   PubMed Web of Science ®Google Scholar
• Mesulam M, Siddique T, Cohen B. Cholinergic denervation in a pure multi-infarct state: observations on CADASIL. Neurology60(7), 1183–1185 (2003).
   PubMed Web of Science ®Google Scholar
• Gray F, Polivka M, Viswanathan A, Baudrimont M, Bousser MG, Chabriat H. Apoptosis in cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy. J. Neuropathol. Exp. Neurol.66(7), 597–607 (2007).
   PubMed Web of Science ®Google Scholar
• Keverne JS, Low WC, Ziabreva I, Court JA, Oakley AE, Kalaria RN. Cholinergic neuronal deficits in CADASIL. Stroke38(1), 188–191 (2007).
   PubMed Web of Science ®Google Scholar
• Sharma P, Wang T, Brown MJ, Schapira AH. Fits and strokes. Lancet358(9276), 120 (2001).
   PubMedGoogle Scholar
• Haan J, Lesnik Oberstein SA, Ferrari MD. Epilepsy in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy. Cerebrovasc. Dis.24(2–3), 316–317 (2007).
   PubMedGoogle Scholar
• Valko PO, Siccoli MM, Schiller A, Wieser HG, Jung HH. Non-convulsive status epilepticus causing focal neurological deficits in CADASIL. J. Neurol. Neurosurg. Psychiatr.78(11), 1287–1289 (2007).
   PubMedGoogle Scholar
• Nakamura T, Watanabe H, Hirayama M et al. CADASIL with NOTCH3 S180C presenting anticipation of onset age and hallucinations. J. Neurol. Sci.238(1–2), 87–91 (2005).
   PubMedGoogle Scholar
• O’Sullivan M, Jarosz JM, Martin RJ, Deasy N, Powell JF, Markus HS. MRI hyperintensities of the temporal lobe and external capsule in patients with CADASIL. Neurology56(5), 628–634 (2001).
   PubMed Web of Science ®Google Scholar
• Singhal S, Rich P, Markus HS. The spatial distribution of MR imaging abnormalities in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy and their relationship to age and clinical features. AJNR Am. J. Neuroradiol.26(10), 2481–2487 (2005).
   PubMed Web of Science ®Google Scholar
• Dichgans M, Holtmannspotter M, Herzog J, Peters N, Bergmann M, Yousry TA. Cerebral microbleeds in CADASIL: a gradient-echo magnetic resonance imaging and autopsy study. Stroke33(1), 67–71 (2002).
   PubMed Web of Science ®Google Scholar
• Viswanathan A , Chabriat H. Cerebral microhemorrhage. Stroke37(2), 550–555 (2006).
   PubMed Web of Science ®Google Scholar
• Lesnik Oberstein SA, van den Boom R, van Buchem MA et al. Cerebral microbleeds in CADASIL. Neurology57(6), 1066–1070 (2001).
   PubMedGoogle Scholar
• Ragoschke-Schumm A, Axer H, Fitzek C et al. Intracerebral haemorrhage in CADASIL. J. Neurol. Neurosurg. Psychiatr.76(11), 1606–1607 (2005).
   PubMedGoogle Scholar
• Choi JC, Kang SY, Kang JH, Park JK. Intracerebral hemorrhages in CADASIL. Neurology67(11), 2042–2044 (2006).
   PubMed Web of Science ®Google Scholar
• Werbrouck BF , De Bleecker JL. Intracerebral haemorrhage in CADASIL. A case report. Acta Neurol. Belg.106(4), 219–221 (2006).
   PubMedGoogle Scholar
• Requena I, Indakoetxea B, Lema C, Santos B, Garcia-Castineira A, Arias M. [Coma associated with migraine]. Rev. Neurol.29(11), 1048–1051 (1999).
   PubMed Web of Science ®Google Scholar
• Le Ber I, Carluer L, Derache N, Lalevee C, Ledoze F, Defer GL. Unusual presentation of CADASIL with reversible coma and confusion. Neurology59(7), 1115–1116 (2002).
   PubMedGoogle Scholar
• Feuerhake F, Volk B, Ostertag CB et al. Reversible coma with raised intracranial pressure: an unusual clinical manifestation of CADASIL. Acta Neuropathol. (Berl.)103(2), 188–192 (2002).
   PubMedGoogle Scholar
• Kleinig TJ, Kimber T, Thompson PD. Acute encephalopathy as the initial symptom of CADASIL. Intern. Med. J.37(11), 786–787 (2007).
   PubMedGoogle Scholar
• Schon F, Martin RJ, Prevett M, Clough C, Enevoldson TP, Markus HS. “CADASIL coma”: an underdiagnosed acute encephalopathy. J. Neurol. Neurosurg. Psychiatr.74(2), 249–252 (2003).
   PubMedGoogle Scholar
• Desmond DW, Moroney JT, Lynch T et al. CADASIL in a North American family: clinical, pathologic, and radiologic findings. Neurology51(3), 844–849 (1998).
   PubMed Web of Science ®Google Scholar
• Kotorii S, Sakae N, Yamada N, Yamanaka H, Fujii N, Nakashima Y. [A case of CADASIL in early stage]. Rinsho Shinkeigaku41(6), 306–309 (2001).
   PubMedGoogle Scholar
• Avila A, Bello J, Maho P, Gomez MI. [A new Spanish family with CADASIL associated with 346C>T mutation of NOTCH3 gene]. Neurologia22(7), 484–487 (2007).
   PubMedGoogle Scholar
• Cumurciuc R, Massin P, Paques M et al. Retinal abnormalities in CADASIL: a retrospective study of 18 patients. J. Neurol. Neurosurg. Psychiatry75(7), 1058–1060 (2004).
   PubMedGoogle Scholar
• Haritoglou C, Rudolph G, Hoops JP, Opherk C, Kampik A, Dichgans M. Retinal vascular abnormalities in CADASIL. Neurology62(7), 1202–1205 (2004).
   PubMedGoogle Scholar
• Rufa A, Malandrini A, Dotti MT, Berti G, Salvadori C, Federico A. Typical pathological changes of CADASIL in the optic nerve. Neurol. Sci.26(4), 271–274 (2005).
   PubMedGoogle Scholar
• Gobron C, Viswanathan A, Bousser MG, Chabriat H. Multiple simultaneous cerebral infarctions in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy. Cerebrovasc. Dis.22(5–6), 445–446 (2006).
   PubMedGoogle Scholar
• Rubio A, Rifkin D, Powers JM et al. Phenotypic variability of CADASIL and novel morphologic findings. Acta Neuropathol.94(3), 247–254 (1997).
   PubMed Web of Science ®Google Scholar
• Cocho D, Martí-Fábregas J, Rio E, Gallardo E, Baiget M, Martí-Vilalta JL. [A new mutation of CADASIL disease in a patient with cerebellar stroke]. Neurologia21(9), 589 (2006).
   Google Scholar
• Hutchinson M, O’Riordan J, Javed M et al. Familial hemiplegic migraine and autosomal dominant arteriopathy with leukoencephalopathy (CADASIL). Ann. Neurol.38(5), 817–824 (1995).
   PubMedGoogle Scholar
• Cumurciuc R, Guichard JP, Reizine D, Gray F, Bousser MG, Chabriat H. Dilation of Virchow–Robin spaces in CADASIL. Eur. J. Neurol.13(2), 187–190 (2006).
   PubMedGoogle Scholar
• Pescini F, Sarti C, Pantoni L et al. Cerebellar arteriovenous malformation and vertebral artery aneurysm in a CADASIL patient. Acta Neurol. Scand.113(1), 62–63 (2006).
   PubMedGoogle Scholar
• Ratzinger G, Ransmayr G, Romani N, Zelger B. CADASIL – an unusual manifestation with prominent cutaneous involvement. Br. J. Dermatol.152(2), 346–349 (2005).
   PubMedGoogle Scholar
• Saiki S, Sakai K, Saiki M et al. Varicose veins associated with CADASIL result from a novel mutation in the NOTCH3 gene. Neurology67(2), 337–339 (2006).
   PubMedGoogle Scholar
• Van Gerpen JA, Ahlskog JE, Petty GW. Progressive supranuclear palsy phenotype secondary to CADASIL. Parkinsonism Relat. Disord.9(6), 367–369 (2003).
   PubMedGoogle Scholar
• Miranda M, Dichgans M, Slachevsky A et al. CADASIL presenting with a movement disorder: a clinical study of a Chilean kindred. Mov. Disord.21(7), 1008–1012 (2006).
   PubMedGoogle Scholar
• Dichgans M, Wick M, Gasser T. Cerebrospinal fluid findings in CADASIL. Neurology53(1), 233 (1999).
   PubMedGoogle Scholar
• Unlu M, De Lange RP, de Silva R, Kalaria R, St Clair D. Detection of complement factor B in the cerebrospinal fluid of patients with cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy disease using two-dimensional gel electrophoresis and mass spectrometry. Neurosci. Lett.282(3), 149–152 (2000).
   PubMedGoogle Scholar
• Broadley SA, Sawcer SJ, Chataway SJ et al. No association between multiple sclerosis and the NOTCH3 gene responsible for cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL). J. Neurol. Neurosurg. Psychiatry71(1), 97–99 (2001).
   PubMedGoogle Scholar
• Ruibal M, de Arce A, Martínez Pérez-Balsa A et al. [X Annual Meeting of the Neurology Society of Basque Country]. Revista Neurología23(122), 922 (1995).
   Google Scholar
• Escary JL, Cecillon M, Maciazek J, Lathrop M, Tournier-Lasserve E, Joutel A. Evaluation of DHPLC analysis in mutational scanning of NOTCH3, a gene with a high G-C content. Hum. Mutat.16(6), 518–526 (2000).
   PubMedGoogle Scholar
• Joutel A, Favrole P, Labauge P et al. Skin biopsy immunostaining with a Notch3 monoclonal antibody for CADASIL diagnosis. Lancet358(9298), 2049–2051 (2001).
   PubMed Web of Science ®Google Scholar
• Baudrimont M, Dubas F, Joutel A, Tournier-Lasserve E, Bousser MG. Autosomal dominant leukoencephalopathy and subcortical ischemic stroke. A clinicopathological study. Stroke24(1), 122–125 (1993).
   PubMed Web of Science ®Google Scholar
• Malandrini A, Gaudiano C, Gambelli S et al. Diagnostic value of ultrastructural skin biopsy studies in CADASIL. Neurology68(17), 1430–1432 (2007).
   PubMed Web of Science ®Google Scholar
• Fouillade C, Chabriat H, Riant F et al. Activating NOTCH3 mutation in a patient with small-vessel-disease of the brain. Hum. Mutat.29(3), 452 (2008).
   PubMed Web of Science ®Google Scholar
• Ferrari MD, Roon KI, Lipton RB, Goadsby PJ. Oral triptans (serotonin 5-HT [1B/1D] agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet358(9294), 1668–1675 (2001).
   PubMed Web of Science ®Google Scholar
• Holroyd KA, Penzien DB, Cordingley GE. Propranolol in the management of recurrent migraine: a meta-analytic review. Headache31(5), 333–340 (1991).
   PubMed Web of Science ®Google Scholar
• Schurks M, Diener HC, Goadsby P. Update on the prophylaxis of migraine. Curr. Treat. Options Neurol.10(1), 20–29 (2008).
   PubMed Web of Science ®Google Scholar
• Couch JR, Ziegler DK, Hassanein R. Amitriptyline in the prophylaxis of migraine. Effectiveness and relationship of antimigraine and antidepressant effects. Neurology26(2), 121–127 (1976).
   PubMed Web of Science ®Google Scholar
• Silberstein SD, Neto W, Schmitt J, Jacobs D. Topiramate in migraine prevention: results of a large controlled trial. Arch. Neurol.61(4), 490–495 (2004).
   PubMed Web of Science ®Google Scholar
• Shaygannejad V, Janghorbani M, Ghorbani A, Ashtary F, Zakizade N, Nasr V. Comparison of the effect of topiramate and sodium valporate in migraine prevention: a randomized blinded crossover study. Headache46(4), 642–648 (2006).
   PubMed Web of Science ®Google Scholar
• Mathew NT, Rapoport A, Saper J et al. Efficacy of gabapentin in migraine prophylaxis. Headache41(2), 119–128 (2001).
   PubMed Web of Science ®Google Scholar
• Steiner TJ, Ahmed F, Findley LJ, MacGregor EA, Wilkinson M. S-fluoxetine in the prophylaxis of migraine: a Phase II double-blind randomized placebo-controlled study. Cephalalgia18(5), 283–286 (1998).
   PubMed Web of Science ®Google Scholar
• Forteza AM, Brozman B, Rabinstein AA, Romano JG, Bradley WG. Acetazolamide for the treatment of migraine with aura in CADASIL. Neurology57(11), 2144–2145 (2001).
   PubMed Web of Science ®Google Scholar
• Chabriat H, Pappata S, Ostergaard L et al. Cerebral hemodynamics in CADASIL before and after acetazolamide challenge assessed with MRI bolus tracking. Stroke31(8), 1904–1912 (2000).
   PubMed Web of Science ®Google Scholar
• Chabriat H, Vahedi K, Iba-Zizen MT et al. Clinical spectrum of CADASIL: a study of 7 families. Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy. Lancet346(8980), 934–939 (1995).
   PubMed Web of Science ®Google Scholar
• Dichgans M, Petersen D. Angiographic complications in CADASIL. Lancet349(9054), 776–777 (1997).
   PubMedGoogle Scholar
• Singhal S, Bevan S, Barrick T, Rich P, Markus HS. The influence of genetic and cardiovascular risk factors on the CADASIL phenotype. Brain127(Pt 9), 2031–2038 (2004).
   PubMed Web of Science ®Google Scholar
• Holtmannspotter M, Peters N, Opherk C et al. Diffusion magnetic resonance histograms as a surrogate marker and predictor of disease progression in CADASIL: a two-year follow-up study. Stroke36(12), 2559–2565 (2005).
   PubMed Web of Science ®Google Scholar
• Viswanathan A, Guichard JP, Gschwendtner A et al. Blood pressure and haemoglobin A1c are associated with microhaemorrhage in CADASIL: a two-centre cohort study. Brain129(Pt 9), 2375–2383 (2006).
   PubMedGoogle Scholar
• Peters N, Holtmannspotter M, Opherk C et al. Brain volume changes in CADASIL: a serial MRI study in pure subcortical ischemic vascular disease. Neurology66(10), 1517–1522 (2006).
   PubMed Web of Science ®Google Scholar
• Oh JH, Lee JS, Kang SY, Kang JH, Choi JC. Aspirin-associated intracerebral hemorrhage in a patient with CADASIL. Clin. Neurol. Neurosurg.110(4), 384–386 (2008).
   PubMedGoogle Scholar
• European Stroke Organisation Executive Committee. Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. Cerebrovasc. Dis.25(5), 457–507 (2008).
   PubMed Web of Science ®Google Scholar
• Costa J, Ferro JM, Matias-Guiu J, varez-Sabin J, Torres F. Triflusal for preventing serious vascular events in people at high risk. Cochrane Database Syst. Rev.3, CD004296 (2005).
   Google Scholar
• Peters N, Freilinger T, Opherk C, Pfefferkorn T, Dichgans M. Effects of short term atorvastatin treatment on cerebral hemodynamics in CADASIL. J. Neurol. Sci.260(1–2), 100–105 (2007).
   PubMed Web of Science ®Google Scholar
• Lauterbach EC , Schweri MM. Amelioration of pseudobulbar affect by fluoxetine: possible alteration of dopamine-related pathophysiology by a selective serotonin reuptake inhibitor. J. Clin. Psychopharmacol.11(6), 392–393 (1991).
   PubMedGoogle Scholar
• Chen Y, Guo JJ, Li H, Wulsin L, Patel NC. Risk of cerebrovascular events associated with antidepressant use in patients with depression: a population-based, nested case–control study. Ann. Pharmacother.42(2), 177–184 (2008).
   PubMed Web of Science ®Google Scholar
• Swenson JR, Doucette S, Fergusson D. Adverse cardiovascular events in antidepressant trials involving high-risk patients: a systematic review of randomized trials. Can. J. Psychiatry51(14), 923–929 (2006).
   PubMed Web of Science ®Google Scholar
• Kharofa J, Sekar P, Haverbusch M et al. Selective serotonin reuptake inhibitors and risk of hemorrhagic stroke. Stroke38(11), 3049–3051 (2007).
   PubMed Web of Science ®Google Scholar
• Dichgans M, Markus HS, Salloway S et al. Donepezil in patients with subcortical vascular cognitive impairment: a randomised double-blind trial in CADASIL. Lancet Neurol.7(4), 310–318 (2008).
   PubMed Web of Science ®Google Scholar
• Schneider LS. Does donepezil improve executive function in patients with CADASIL? Lancet Neurol.7(4), 287–289 (2008).
   PubMed Web of Science ®Google Scholar
• Roman GC. Cholinergic dysfunction in vascular dementia. Curr. Psychiatry Rep.7(1), 18–26 (2005).
   PubMedGoogle Scholar
• Posada IJ, Ferrero Ros M, López Valdés E, Goñi Imizcoz M. [Galantamina in CADASIL dementia]. Neurologia22(9), 722 (2007).
   Google Scholar
• Areosa SA, Sherriff F, McShane R. Memantine for dementia. Cochrane Database Syst. Rev.3, CD003154 (2005).
   PubMedGoogle Scholar
• Qaseem A, Snow V, Cross JT Jr et al. Current pharmacologic treatment of dementia: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians. Ann. Intern. Med.148(5), 370–378 (2008).
   PubMed Web of Science ®Google Scholar
• Grosset DG, Ebrahim S, Bone I, Warlow C. Stroke in pregnancy and the puerperium: what magnitude of risk? J. Neurol. Neurosurg. Psychiatr.58(2), 129–131 (1995).
   PubMedGoogle Scholar
• Roine S, Poyhonen M, Timonen S et al. Neurologic symptoms are common during gestation and puerperium in CADASIL. Neurology64(8), 1441–1443 (2005).
   PubMedGoogle Scholar
• Roberts JM, Taylor RN, Musci TJ, Rodgers GM, Hubel CA, McLaughlin MK. Preeclampsia: an endothelial cell disorder. Am. J. Obstet. Gynecol.161(5), 1200–1204 (1989).
   PubMed Web of Science ®Google Scholar
• Peters N, Freilinger T, Opherk C, Pfefferkorn T, Dichgans M. Enhanced L-arginine-induced vasoreactivity suggests endothelial dysfunction in CADASIL. J. Neurol.255(8), 1203–1208 (2008).
   PubMedGoogle Scholar
• Facchinetti F, Saade GR, Neri I, Pizzi C, Longo M, Volpe A. l-arginine supplementation in patients with gestational hypertension: a pilot study. Hypertens. Pregnancy26(1), 121–130 (2007).
   PubMed Web of Science ®Google Scholar
• Milunsky A, Konialis C, Shim SH et al. The prenatal diagnosis of cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) by mutation analysis. Prenat. Diagn.25(11), 1057–1058 (2005).
   PubMedGoogle Scholar
• Konialis C, Hagnefelt B, Kokkali G, Pantos C, Pangalos C. Pregnancy following preimplantation genetic diagnosis of cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL). Prenat. Diagn.27(11), 1079–1083 (2007).
   PubMedGoogle Scholar
• Wondrak GT. Reactivity-based drug discovery using vitamin B6-derived pharmacophores. Mini Rev. Med. Chem.8(5), 519–528 (2008).
   PubMedGoogle Scholar
• Qin W, Yang T, Ho L et al. Neuronal SIRT1 activation as a novel mechanism underlying the prevention of Alzheimer disease amyloid neuropathology by calorie restriction. J. Biol. Chem.281(31), 21745–21754 (2006).
   PubMed Web of Science ®Google Scholar
• Pallas M, Verdaguer E, Tajes M, Gutierrez-Cuesta J, Camins A. Modulation of sirtuins: new targets for antiageing. Recent Patents CNS Drug Discov.3(1), 61–69 (2008).
   PubMedGoogle Scholar
• Elliott PJ, Jirousek M. Sirtuins: novel targets for metabolic disease. Curr. Opin. Investig. Drugs9(4), 371–378 (2008).
   PubMed Web of Science ®Google Scholar
• Dong Y, Hassan A, Zhang Z et al. Yield of screening for CADASIL mutations in lacunar stroke and leukoaraiosis. Stroke34(1), 203–205 (2003).
   PubMed Web of Science ®Google Scholar
• Trojano L, Ragno M, Manca A, Caruso G. A kindred affected by cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL). A 2-year neuropsychological follow-up. J. Neurol.245(4), 217–222 (1998).
   PubMed Web of Science ®Google Scholar
• Amberla K, Waljas M, Tuominen S et al. Insidious cognitive decline in CADASIL. Stroke35(7), 1598–1602 (2004).
   PubMed Web of Science ®Google Scholar
• Peters N, Opherk C, Danek A et al. The pattern of cognitive performance in CADASIL: a monogenic condition leading to subcortical ischemic vascular dementia. Am. J. Psychiatry162(11), 2078–2085 (2005).
   PubMed Web of Science ®Google Scholar
• Benisty S, Hernandez K, Viswanathan A et al. Diagnostic criteria of vascular dementia in CADASIL. Stroke39(3), 838–844 (2008).
   PubMed Web of Science ®Google Scholar
• Pfefferkorn T, Von Stuckrad-Barre S, Herzog J et al. Reduced cerebrovascular CO2 reactivity in CADASIL: a transcranial Doppler sonography study. Stroke32(1), 17–21 (2001).
   PubMed Web of Science ®Google Scholar
• Liebetrau M, Herzog J, Kloss CU, Hamann GF, Dichgans M. Prolonged cerebral transit time in CADASIL: a transcranial ultrasound study. Stroke33(2), 509–512 (2002).
   PubMed Web of Science ®Google Scholar
• Harju M, Tuominen S, Summanen P et al. Scanning laser Doppler flowmetry shows reduced retinal capillary blood flow in CADASIL. Stroke35(11), 2449–2452 (2004).
   PubMedGoogle Scholar
• Singhal S, Markus HS. Cerebrovascular reactivity and dynamic autoregulation in nondemented patients with CADASIL (cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy). J. Neurol.252(2), 163–167 (2005).
   PubMedGoogle Scholar
• Manabe Y, Murakami T, Iwatsuki K et al. Nocturnal blood pressure dip in CADASIL. J. Neurol. Sci.193(1), 13–16 (2001).
   PubMedGoogle Scholar
• Hussain MB, Singhal S, Markus HS, Singer DR. Abnormal vasoconstrictor responses to angiotensin II and noradrenaline in isolated small arteries from patients with cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL). Stroke35(4), 853–858 (2004).
   PubMedGoogle Scholar
• Stenborg A, Kalimo H, Viitanen M, Terent A, Lind L. Impaired endothelial function of forearm resistance arteries in CADASIL patients. Stroke38(10), 2692–2697 (2007).
   PubMedGoogle Scholar
• Mellies JK, Baumer T, Muller JA et al. SPECT study of a German CADASIL family: a phenotype with migraine and progressive dementia only. Neurology50(6), 1715–1721 (1998).
   PubMedGoogle Scholar
• Tatsch K, Koch W, Linke R et al. Cortical hypometabolism and crossed cerebellar diaschisis suggest subcortically induced disconnection in CADASIL: an 18F-FDG PET study. J. Nucl. Med.44(6), 862–869 (2003).
   PubMedGoogle Scholar
• Tuominen S, Miao Q, Kurki T et al. Positron emission tomography examination of cerebral blood flow and glucose metabolism in young CADASIL patients. Stroke35(5), 1063–1067 (2004).
   PubMed Web of Science ®Google Scholar
• Brulin P, Godfraind C, Leteurtre E, Ruchoux MM. Morphometric analysis of ultrastructural vascular changes in CADASIL: analysis of 50 skin biopsy specimens and pathogenic implications. Acta Neuropathol.104(3), 241–248 (2002).
   PubMedGoogle Scholar
• Auer DP, Schirmer T, Heidenreich JO et al. Altered white and gray matter metabolism in CADASIL: a proton MR spectroscopy and 1H-MRSI study. Neurology56(5), 635–642 (2001).
   PubMed Web of Science ®Google Scholar
• Macri MA, Colonnese C, Garreffa G et al. A chemical shift imaging study on regional metabolite distribution in a CADASIL family. Magn. Reson. Imaging24(4), 443–447 (2006).
   PubMedGoogle Scholar
• Jouvent E, Viswanathan A, Mangin JF et al. Brain atrophy is related to lacunar lesions and tissue microstructural changes in CADASIL. Stroke38(6), 1786–1790 (2007).
   PubMedGoogle Scholar
• Liem MK, van der Grond J, Haan J et al. Lacunar infarcts are the main correlate with cognitive dysfunction in CADASIL. Stroke38(3), 923–928 (2007).
   PubMed Web of Science ®Google Scholar
• O’Sullivan M, Ngo E, Viswanathan A et al. Hippocampal volume is an independent predictor of cognitive performance in CADASIL. Neurobiol. Aging doi:10.1016/j.neurobiolaging.2007.09.002 (2007) (Epub ahead of print).
   Google Scholar
• Viswanathan A, Gschwendtner A, Guichard JP et al. Lacunar lesions are independently associated with disability and cognitive impairment in CADASIL. Neurology69(2), 172–179 (2007).
   PubMed Web of Science ®Google Scholar
• Jouvent E, Mangin JF, Porcher R et al. Cortical changes in cerebral small vessel diseases: a 3D MRI study of cortical morphology in CADASIL. Brain131(Pt 8), 2201–2208 (2008).
   PubMedGoogle Scholar
• Chabriat H, Pappata S, Poupon C et al. Clinical severity in CADASIL related to ultrastructural damage in white matter: in vivo study with diffusion tensor MRI. Stroke30(12), 2637–2643 (1999).
   PubMed Web of Science ®Google Scholar
• Iannucci G, Dichgans M, Rovaris M et al. Correlations between clinical findings and magnetization transfer imaging metrics of tissue damage in individuals with cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy. Stroke32(3), 643–648 (2001).
   PubMed Web of Science ®Google Scholar
• Molko N, Pappata S, Mangin JF et al. Diffusion tensor imaging study of subcortical gray matter in cadasil. Stroke32(9), 2049–2054 (2001).
   PubMed Web of Science ®Google Scholar
• Rocca MA, Filippi M, Herzog J et al. A magnetic resonance imaging study of the cervical cord of patients with CADASIL. Neurology56(10), 1392–1394 (2001).
   PubMedGoogle Scholar
• Molko N, Pappata S, Mangin JF et al. Monitoring disease progression in CADASIL with diffusion magnetic resonance imaging: a study with whole brain histogram analysis. Stroke33(12), 2902–2908 (2002).
   PubMed Web of Science ®Google Scholar
• Dichgans M, Putz B, Boos D, Auer DP. Role of subvoxel free fluid on diffusion parameters in brain tissue with cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy and its correlation with physical disability: histogram analysis of standard and fluid-attenuated MR diffusion. AJNR Am. J. Neuroradiol.24(6), 1083–1089 (2003).
   PubMedGoogle Scholar
• Holtmannspotter M, Peters N, Opherk C et al. Diffusion magnetic resonance histograms as a surrogate marker and predictor of disease progression in CADASIL: a two-year follow-up study. Stroke36(12), 2559–2565 (2005).
   PubMed Web of Science ®Google Scholar
• Bruening R, Dichgans M, Berchtenbreiter C et al. Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy: decrease in regional cerebral blood volume in hyperintense subcortical lesions inversely correlates with disability and cognitive performance. AJNR Am. J. Neuroradiol.22(7), 1268–1274 (2001).
   PubMedGoogle Scholar
• Manganelli F, Ragno M, Cacchio G et al. Motor cortex cholinergic dysfunction in CADASIL: a transcranial magnetic demonstration. Clin. Neurophysiol.119(2), 351–355 (2008).
   PubMed Web of Science ®Google Scholar